Melanoma-induced brain metastases

Expert Review of Anticancer Therapy

Volumn 8, Issue 5, 2008, Pages 743-755

  McWilliams, Robert R ^a   Rao, Ravi D ^a   Buckner, Jan C ^a   Link, Michael J ^a   Markovic, Svetomir ^a   Brown, Paul D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Brain; Melanoma; Metastases; Radiosurgery; Treatment

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CELL ANTIBODY; CISPLATIN; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EFAPROXIRAL; ETOPOSIDE; FOTEMUSTINE; IPILUMUMAB; TEMOZOLOMIDE; THALIDOMIDE; TICILIMUMAB; ALKYLATING AGENT;

BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER SURGERY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CRANIOTOMY; ENTERITIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MELANOMA; MULTIPLE CYCLE TREATMENT; PROGNOSIS; PUBLICATION; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; STEREOTACTIC RADIOSURGERY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; BRAIN TUMOR; IMMUNOTHERAPY; MEGAVOLTAGE RADIOTHERAPY; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOSURGERY; SKIN TUMOR;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA; RADIOSURGERY; RADIOTHERAPY, HIGH-ENERGY; SKIN NEOPLASMS;

EID: 45849101270     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.5.743     Document Type: Review

References (98)

1. de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 43(7), 3427-3433 (1983).
2. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am. J. Surg. 135(6), 807-810 (1978).
3. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42(2), 660-668 (1978).
4. Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J. Neurooncol. 1(4), 313-317 (1983).
5. Sze G, Shin J, Krol G, Johnson C, Liu D, Deck MD. Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT. Radiology 168(1), 187-194 (1988).
6. Davis PC, Hudgins PA, Peterman SB, Hoffman JC Jr. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJNR Am. J. Neuroradiol. 12 (2), 293-300 (1991).
7. Taphoorn MJ, Heimans JJ, Kaiser MC, de Slegte RG, Crezee FC, Valk J. Imaging of brain metastases. Comparison of computerized tomography (CT) and magnetic resonance imaging (MRI). Neuroradiology 31(5), 391-395 (1989).
8. Boni R, Boni RA, Steinert H et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br. J. Dermatol 132(4), 556-562 (1995).
9. Einhorn LH, Burgess MA, Vallejos C et al. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res. 34(8), 1995-2004 (1974).
10. Budman DR, Camacho E, Wittes RE. The current causes of death in patients with malignant melanoma. Eur. J. Cancer 14(4), 327-330 (1978).
11. Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37(4), 745-751 (1997).
12. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94(8), 2265-2272 (2002).
13. Morris SL, Low SH, A'Hern RP et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br. J. Cancer 91(5), 829-833 (2004).
14. Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin. Proc. 79(12), 1489-1494 (2004).
15. Forsyth PA, Weaver S, Fulton D et al. Prophylactic anticonvulsants in patients with brain tumour. Can. J. Neurol. Sci. 30(2), 106-112 (2003).
16. Glantz MJ, Cole BF, Friedberg MH et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46(4), 985-991 (1996).
17. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response pf human malignant melanoma cells grown in vitro. Cancer Res. 31(6), 830-833 (1971).
18. Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer 45(4), 679-683 (1980).
19. Cooper JS, Carella R. Radiotherapy of in tracerebral metastatic malignant melanoma. Radiology 134(3), 735-738 (1980).
20. Stridsklev IC, Hagen S, Klepp O. Radiation therapy for brain metastases from malignant melanoma. Acta Radiol. Oncol. 23(4), 231-235 (1984).
21. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88(1), 11-20 (1998).
22. Ellerhorst J, Strom E, Nardone E, McCutcheon I. Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases. Int. J. Radiat. Oncol. Biol. Phys. 49(1), 93-97 (2001).
23. Stone A, Cooper J, Koenig KL, Golfinos JG, Oratz R. A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest. 22(4), 492-497 (2004).
24. Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer 53(11), 2550-2552 (1984).
25. Gottlieb JA, Frei E III, Luce JK. An evaluation of the management of patients with cerebral metastases from malignant melanoma. Cancer 29(3), 791-705 (1972).
26. Fell DA, Leavens ME, McBride CM. Surgical versus nonsurgical management of metastatic melanoma of the brain. Neurosurgery 7(3), 238-242 (1980).
27. Hornsey S. The radiosensitivity of melanoma cells in culture. Br. J. Radiol. 45(530), 158 (1972).
28. Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol. Oncol. 25(1), 1-10 (1986).
29. Kleeberg UR, Suciu S, Brocker EB et al. Final results of the EORTC 18871/DKG 80-1 randomised Phase III trial, rIFN-α2b versus rIFN-γ versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur. J. Cancer 40(3), 390-402 (2004).
30. Ziegler JC, Cooper JS. Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 12(10), 1839-1842 (1986).
31. Vlock DR, Kirkwood JM, Leutzinger C, Kapp DS, Fischer JJ. High-dose fraction radiation therapy for intracranial metastases of malignant melanoma: a comparison with low-dose fraction therapy. Cancer 49(11), 2289-2294 (1982).
32. Hagen NA, Cirrincione C, Thaler HT, DeAngelis LM. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 40(1), 158-160 (1990).
33. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J. Neurosurg. 93(1), 9-18 (2000).
34. Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17), 1485-1489 (1998).
35. Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J. Neurosurg. 96(3), 552-558 (2002).
36. Katz HR. The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. Int. J. Radiat. Oncol. Biol. Phys. 7(7), 897-906 (1981).
37. Bremer AM, West CR, Didolkar MS. An evaluation of the surgical management of melanoma of the brain. J. Surg. Oncol. 10(3), 211-219 (1978).
38. Patchell RA, Tibbs FA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322(8), 494-500 (1990).
39. Noordijk EM, Vecht CJ, Haaxma-Reiche H et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int. J. Radiat. Oncol. Biol. Phys. 29(4), 711-717 (1994).
40. Konstadoulakis MM, Messaris E, Zografos G, Androulakis G, Karakousis C. Prognostic factors in malignant melanoma patients with solitary or mutiple brain metastases. Is there a role for surgery? J. Neurosurg. Sci. 44(4), 211-218 (2000).
41. Wornom IL III, Smith JW Soong SJ, McElvein R, Urist MM, Balch CM. Surgery as palliative treatment for distant metastases of melanoma. Ann. Surg. 204(2), 181-185 (1986).
42. Bindal AK, Bindal RK, Hess KR et al. Surgery versus radiosurgery in the treatment of brain metastasis. J. Neurosurg. 84(5), 748-754 (1996).
43. O'Neill BP, Iturria NJ, Link MJ, Pollock BE, Ballman KV, O'Fallon JR. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 55 (5), 1169-1176 (2003).
44. Muacevic A, Wowra B, Kreth F et al. A randomized trial of surgery and radiotherapy versus radiosurgery alone in the treatment of single metastasis to the brain. In: Deutscher Krebskongress. Berlin, Germany, 22-26 March 2006 (Abstract).
45. Pollock BE, Brown PD, Foote RL, Stafford SL, Schomberg PJ. Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J. Neurooncol. 61(1), 73-80 (2003).
46. Somaza S, Kondziolka D, Lunsford LD, Kirkwood JM, Flickinger JC. Stereotactic radiosurgery for cerebral metastatic melanoma. J. Neurosurg. 79 (5), 661-666 (1993).
47. Fife KM, Colman MH, Stevens GN et al. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 22(7), 1293-1300 (2004).
48. Seung SK, Sneed PK, McDermott MW et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J. Sci. Am. 4(2), 103-109 (1998).
49. Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int. J. Radiat. Oncol. Biol. Phys. 42(3), 581-589 (1998).
50. Grob JJ, Regis J, Laurans R et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancerologie Cutanee. Eur. J. Cancer 34(8), 1187-1192 (1998).
51. Lavine SD, Petrovich Z, Cohen-Gadol AA et al. Gamma knife radiosurgery fbr metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 44(1), 59-64 (1999).
52. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL. Stereotactic radiosurgery for patients with 'radioresistant' brain metastases. Neurosurgery 51(3), 656-665; discussion 665-657 (2002).
53. Mingione V, Oliveira M, Prasad D, Steiner M, Steiner L. Gamma surgery for melanoma metastases in the brain. J. Neurosurg. 96(3), 544-551 (2002).
54. Selek U, Chang EL, Hassenbusch. SJ 3fd et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int. J. Radiat. Oncol. Biol. Phys. 59(4), 1097-1106 (2004).
55. Radbill AE, Fiveash JF, Falkenberg ET et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 101(4), 825-833 (2004).
56. Marion R, O'Neill A, Knisely J et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J. Clin. Oncol. 23(34), 9870-8876 (2005).
57. Samlowski WE, Watson GA, Wang M et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 109(9), 1855-1862 (2007).
58. Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363(9422), 1665-1672 (2004).
59. Gieger M, Wu JK, Ling MN, Wazer D, Tsai JS, Engler MJ. Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat. Oncol. Investig. 5(2), 72-80 (1997).
60. Baldwin Drew W, Raizer JJ, Panageas KS, Houghton AN; NYU School of Medicine, Memorial Sloan-Kettering Cancer Center. Identification of prognostic factors in patients with metastatic melanoma in the brain. Presented at: 2002 ASCO Annual Meeting. Orlando, FL, USA 18-21 May 2002.
61. Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21), 2483-2491 (2006).
62. Sawrie SM, Gurthrie BL, Spencer SA et al. Predictors of distant brain recurrence for newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int. J. Radiat. Oncol. Biol. Phys. 66(3 Suppl. 1), S241-S242 (2006).
63. Regine WF, Huhn JL, Patchell RA et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int. J. Radiat. Oncol Biol. Phys. 52(2), 333-338 (2002); erratum in Int. J. Radiat. Oncol. Biol. Phys. 53(1), 259 (2002).
64. Pavlick AC. Chemotherapy approaches to melanoma. Dermatol. Clin. 20(4), 709-712 (2002).
65. Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastates from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85(7), 1599-1605 (1999).
66. Beretta G, Bonadonna G, Cascinelli N, Morabito A, Veronesi U. Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study. Cancer Treat. Rep. 60(1), 33-40 (1976).
67. Boaziz C, Breau JL, Morere JF, Israel L. Metastases cerebrales des melanomes malins. Bull. Cancer 78(4), 347-353 (1991).
68. Kleeberg UR, Engel E, Israels P et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre Phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res. 5(3), 195-200 (1995).
69. Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66(9), 1873-1878 (1990).
70. Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N. Engl. J. Med. 345(8), 621-622 (2001).
71. Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18(1), 158-166 (2000); erratum in J. Clin. Oncol. 18(11), 2351 (2000).
72. Bleehen NM, Newlands ES, Lee SM et al. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 13(4), 910-913 (1995).
73. Bafaloukos D, Tsoutsos D, Fountzilas G et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res. 14(4), 289-294 (2004).
74. Agarwala SS, Kirkwood JM, Gore M et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a Phase II study. J. Clin. Oncol. 22(11), 2101-2107 (2004).
75. Hwu WJ, Krown SE, Menell JH et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. 21(17), 3351-3356 (2003).
76. Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol. 2(10), 634-635 (2001).
77. Bennett CL, Schumock GT, Desai AA et al. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am. J. Med. 113(7), 603-606 (2002).
78. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13(4), 1253-1259 (2007).
79. Perez DG, Suman V, Amatruda T et al. Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. J. Clin. Oncol. 25(18 Suppl.), 8560 (2007) (Abstract).
80. Mornex F, Thomas L, Mohr P et al. Essai de Phase III randomise comparant la fotemustine scule ou associee a une irradiation encephalique dans les metastases cerebrales de melanome. Cancer Radiother. 7(1), 1-8 (2003).
81. Dardoufas AM, Skarleas C, Kouloulias P et al. Concomitant temozolomide (TMZ) and radiotherapy (RT) followed by adjuvant treatment with temozolomide in patients with brain metastases from solid tumours. In: 2001 ASCO Annual Meeting. San Francisco, CA, USA 12-15 May 2001.
82. Margolin K, Atkins B, Thompson A et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a Phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 128(4), 214-218 (2002).
83. Atkins MB, Sosman J, Agarwala S et al. A Cytokine Working Group Phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma. J. Clin. Oncol. 23(16S), (2005) (Abstract 7552).
84. Shaw E, Scott C, Suh J et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the radiation therapy oncology group recursive partitioning analysis brain metastases database. J Clin. Oncol. 21(12), 2364-2371 (2003).
85. Suh JH, Stea B, Nabid A et al. Phase III study of efaproximl as an adjunct to whole-brain radiation therapy for brain metastases. J. Clin. Oncol. 24(1), 106-114 (2006).
86. Guirguis LM, Yang JC, White DE et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J. Immunother. 25(1), 82-87 (2002).
87. Spitler LE, Wong P, Sagebiel R. Combined immunotherapy of malignant melanoma. Unusual survival following cerebral metastasis. Arch. Dermatol. 114(10), 1501-1504 (1978).
88. Savas B, Arslan G, Gelen T, Karpuzoglu G, Ozkaynak C. Multidrug resistant malignant melanoma with intracranial metastasis. responding to immunotherapy. Anticancer Res. 19(5C), 4413-4420 (1999).
89. Boasberg PD, O'Day SJ, Kristedja TS et al. Biochemotherapy for metastatic melanoma with limited central nervous system involvement. Oncology 64(4), 328-335 (2003).
90. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13(22 Pt 1), 6681-6688 (2007).
91. Gomez-Navarro J, Antonia S, Sosman J et al. Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a Phase I/II study. J. Clin. Oncol. 25(18 Suppl.), 8524 (2007) (Abstract).
92. Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 25(7), 613-631 (2007).
93. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J. Clin. Oncol. 12(3), 627-642 (1994).
94. Fogarty GT, Tartaguia C. The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cutaneous melanoma. Clin. Oncol. 18(4), 360-362 (2006).
95. Agarwala SS, Keilholz U, Hogg D et al. Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J. Clin. Oncol. 25(18 Suppl.), 8510 (2007) (Abstract).
96. Rao RD, Holtan SG, Ingle JN et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106(2), 375-382 (2006).
97. Seung SK, Shu HK, McDermott MW, Sneed PK Larson DA. Stereotactic radiosurgery for malignant melanoma to the brain. Surg. Clin. North Am. 76(6), 1399-1411 (1996).
98. Mathieu D, Kondziolka D, Cooper PB et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 60(3), 471-481 (2007).